Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more expensive drugs and other treatments.
This research suggests the need for a refinement of the way the National Institute for Health and Clinical Excellence (NICE) gauges the cost-effectiveness of new treatments, say the researchers. It also has implications for the prices that the NHS can afford to pay for new drugs when the value-based pricing (VBP) scheme for all new drugs is introduced by the government in 2014, they add.
The project was funded by the Medical Research Council (MRC) Methodology Research Programme to establish methods that can estimate the cost-effectiveness threshold for NICE, using routinely-available data.
http://www.pharmatimes.com/Article/...ient_reality_into_NHS_spending_decisions.aspx
This research suggests the need for a refinement of the way the National Institute for Health and Clinical Excellence (NICE) gauges the cost-effectiveness of new treatments, say the researchers. It also has implications for the prices that the NHS can afford to pay for new drugs when the value-based pricing (VBP) scheme for all new drugs is introduced by the government in 2014, they add.
The project was funded by the Medical Research Council (MRC) Methodology Research Programme to establish methods that can estimate the cost-effectiveness threshold for NICE, using routinely-available data.
http://www.pharmatimes.com/Article/...ient_reality_into_NHS_spending_decisions.aspx
